Literature DB >> 7967767

Therapy for fungal infections.

G A Sarosi1, S F Davies.   

Abstract

In the past, few pharmacologic agents were available for management of fungal disease. After the early introduction of amphotericin B and miconazole, the more recent advent of several new antifungal agents, including ketoconazole, fluconazole, and itraconazole has expanded the options for treatment of fungal infections. The dramatic increase in number of immunocompromised patients--both those with acquired immunodeficiency syndrome (AIDS) and those with immunosuppression for other reasons, such as organ transplantation--emphasizes the importance of therapeutic strategies for combating systemic mycoses. In this article, we review our personal recommendations for treating histoplasmosis, blastomycosis, coccidioidomycosis, and cryptococcosis, along with other less common fungal infections, and discuss the efficacy and toxic effects of the various antifungal drugs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7967767     DOI: 10.1016/s0025-6196(12)61381-0

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  3 in total

1.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

2.  Conformational properties of amphotericin B amide derivatives--impact on selective toxicity.

Authors:  H Resat; F A Sungur; M Baginski; E Borowski; V Aviyente
Journal:  J Comput Aided Mol Des       Date:  2000-10       Impact factor: 3.686

Review 3.  Endemic mycosis complicating human immunodeficiency virus infection.

Authors:  G A Sarosi; S F DAvies
Journal:  West J Med       Date:  1996-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.